Eli Lilly Delays Retatrutide FDA Filing, Giving Compounders a Break

Eli Lilly (NYSE: LLY) said Thursday it will delay filing for FDA approval of its next-generation weight-loss drug retatrutide until the first quarter. The delay could give compounding pharmacies more time to continue producing cheaper alternatives.

Details of the Action

Lilly was expected to file for retatrutide approval later this year, but now says the submission will be delayed until Q1. The company did not provide an official reason, but analysts suggest additional safety or efficacy data collection may be required.

Company's Position

Lilly has not issued a formal statement on the reason for the delay but reiterated its commitment to developing retatrutide as an important obesity treatment. Retatrutide is an experimental GLP-1/GIP/glucagon receptor agonist expected to be more potent than current obesity drugs.

Precedents and Context

The news comes as Lilly faces increasing competition from compounding pharmacies producing unapproved versions of its obesity drugs like tirzepatide (Mounjaro/Zepbound). Lilly has filed lawsuits against some compounders, but the delay in retatrutide's filing may give them more breathing room.

Potential Financial Impact

The delay may reduce near-term pressure on compounders but does not affect Lilly's current revenue expectations from tirzepatide. Tirzepatide is expected to remain the primary growth driver until retatrutide launches.